<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Monitoring the patient with HIV and chronic hepatitis B virus infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Monitoring the patient with HIV and chronic hepatitis B virus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Monitoring the patient with HIV and chronic hepatitis B virus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Sherman, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chloe L Thio, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Thomas, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H33402171"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the era of potent antiretroviral therapy (ART), end-stage liver disease secondary to chronic hepatitis B virus (HBV) infection remains a leading cause of morbidity and mortality in people living with HIV [<a href="#rid1">1</a>]. Thus, treating and preventing HBV infection are essential in light of the negative impact HIV has on the natural history of chronic hepatitis B infection. Patients with chronic HBV and HIV coinfection should be treated with a regimen that is effective against <strong>both</strong> HIV and HBV. </p><p>However, treatment of HBV in the patient with HIV can be complicated by drug-induced hepatotoxicity, immune constitution syndromes, and toxicity related to medications. Furthermore, regardless of whether the patient is treated, surveillance for development of hepatocellular carcinoma is required.</p><p>Monitoring of the patient with HIV/HBV coinfection, regardless of whether the patient is taking antiviral therapy, will be discussed here. The epidemiology, clinical manifestations, diagnosis, management, and prevention of HBV infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3640.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in patients living with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/16127.html" rel="external">"Pretreatment evaluation of chronic hepatitis B virus infection in the patient with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/15807.html" rel="external">"Prevention of hepatitis B virus infection in adults with HIV"</a>.)</p><p class="headingAnchor" id="H33402194"><span class="h1">PATIENT MONITORING DURING HBV THERAPY</span></p><p class="headingAnchor" id="H2417845"><span class="h2">HBV DNA and aminotransferase monitoring</span><span class="headingEndMark"> — </span>Laboratory monitoring during hepatitis B virus (HBV) therapy includes serial aminotransferases and assessment of viral suppression. We typically monitor HBV DNA and aminotransferases every three months to confirm the viral load is decreasing appropriately (eg, &lt;500 copies/mL by 6 months), we then reduce the frequency to every six months. </p><p>Studies in patients with HBV alone have demonstrated that normalization of aminotransferases and suppression of HBV DNA (with or without HBeAg seroconversion) are associated with improvements in liver histology and lower rates of cirrhosis, hepatic decompensation, and hepatocellular carcinoma [<a href="#rid2">2</a>]. Studies in coinfection suggest similar benefit [<a href="#rid3">3-5</a>]. </p><p class="headingAnchor" id="H33402233"><span class="h2">HBeAg status</span><span class="headingEndMark"> — </span>Based on results of serologic testing, patients with HBV are classified as having either "HBeAg-positive infection" or "HBeAg-negative infection." Patients with HBeAg-positive infection tend to have higher levels of HBV DNA than patients who are HBeAg negative. A more detailed discussion of the significance of HBeAg is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history", section on 'Phases of chronic HBV infection'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are HBeAg positive should have HBeAg and anti-HBe testing repeated every 6 to 12 months to determine if seroconversion (loss of HBeAg with gain of anti-HBe) has occurred. Seroconversion implies a transition from a more active to a less active disease state. (See  <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No monitoring of HBeAg or anti-HBe is required in HBeAg-negative patients, only HBV DNA. In general, HBeAg-negative patients require chronic HBV therapy for an indefinite period of time, regardless of HIV status, since treatment discontinuation is usually associated with virologic rebound. (See  <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Duration and treatment endpoints'</a>.)</p><p></p><p class="headingAnchor" id="H33402304"><span class="h2">Hepatitis B surface antigen</span><span class="headingEndMark"> — </span>The ultimate goal of HBV therapy is to achieve hepatitis B surface antigen (HBsAg) seroconversion, but this occurs in the minority of patients, regardless of HIV status. Annual testing of HBsAg in patients with ongoing HBV DNA suppression is reasonable. If HBsAg seroconversion occurs and ART needs to be altered, then an anti-HBV drug does not need to be included in the new ART regimen, provided the patient has had 6 to 12 months of anti-HBV therapy after HBsAg seroconversion.</p><p class="headingAnchor" id="H33402493"><span class="h1">SCREENING FOR HEPATOCELLULAR CARCINOMA</span><span class="headingEndMark"> — </span>Patients with HIV and chronic hepatitis B infection should be screened for hepatocellular carcinoma (HCC); however, there is no standardized approach. We typically obtain a baseline ultrasound at the time of diagnosis in all patients. We then obtain an ultrasound (with or without alpha fetoprotein [AFP]) every six months in those with evidence of advanced fibrosis or cirrhosis and those over age 40 years. In one study of patients with HIV/HBV coinfection, the incidence of HCC increased in patients in their 40s [<a href="#rid6">6</a>]. </p><p>A more detailed discussion of HCC screening in patients with chronic HBV is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults", section on 'Patients with hepatitis B without cirrhosis'</a>.) </p><p class="headingAnchor" id="H33402500"><span class="h1">MONITORING IN PATIENTS WITH HIV, HBV, AND HCV</span><span class="headingEndMark"> — </span>In patients with hepatitis B virus (HBV) and coexisting hepatitis C virus (HCV) infection, one virus typically predominates over another. During HBV therapy, it is reasonable to assay for HCV RNA, particularly if aminotransferases rise despite declining HBV DNA levels. However, in one small study of 21 patients with HIV, HBV, and HCV coinfection, re-emergence of the less dominant virus was uncommon [<a href="#rid7">7</a>]. </p><p>In the unusual case where a patient with HIV/HBV/HCV tri-infection is not on HBV-active antiretroviral therapy (ART) and receives direct-acting antiviral therapy for HCV, reactivation of HBV may occur. Reactivation has been reported in HBV/HCV-coinfected patients who are either positive only for hepatitis B core antibody (isolated-anti-HBc-positive) or are hepatitis B surface antigen-positive with low or undetectable HBV DNA levels [<a href="#rid8">8</a>]. Thus, if such patients are not started on HBV-active antiretroviral therapy before receiving HCV therapy, these patients should be monitored closely for HBV reactivation. (See  <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.)</p><p class="headingAnchor" id="H33402514"><span class="h1">ABNORMALITIES OF AMINOTRANSFERASES</span><span class="headingEndMark"> — </span>Fluctuations in aminotransferases in the patient coinfected with HIV and HBV may be due to:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic hepatitis B infection </p><p class="bulletIndent1"><span class="glyph">●</span>Immune reconstitution syndrome </p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced liver injury</p><p class="bulletIndent1"><span class="glyph">●</span>Emergence of HBV drug resistance </p><p class="bulletIndent1"><span class="glyph">●</span>Infection with another hepatitis virus</p><p class="bulletIndent1"><span class="glyph">●</span>Steatotic liver disease</p><p></p><p class="headingAnchor" id="H33402521"><span class="h2">Chronic hepatitis B virus infection</span><span class="headingEndMark"> — </span>HIV/HBV-coinfected patients may have waxing and waning aminotransferases during untreated infection. Data in patients with HBV alone suggest that serial flares of liver function tests can lead to increased rates of fibrosis progression. </p><p>Mild increases in liver function tests may also occur in the setting of HBV treatment, which are often seen incidentally with routine laboratory monitoring. </p><p class="headingAnchor" id="H33402528"><span class="h2">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>Immune reconstitution after initiation of antiretroviral therapy (ART) in the coinfected patient can be associated with elevation in aminotransferases, possibly because HBV is primarily an immune-mediated disease. Risk factors for HBV-related immune reconstitution include a high level of HBV viremia and a low CD4 count [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>Patients should be instructed to call their healthcare provider if they should develop symptoms of acute hepatitis with right upper quadrant pain, nausea, vomiting, anorexia, jaundice, or icterus. Close laboratory monitoring of aminotransferases is suggested during the first three months of therapy (eg, every six weeks), particularly in those with low CD4 cell counts. </p><p>Most cases of immune reconstitution inflammatory syndrome resolve uneventfully; however, the patient with cirrhosis is at risk for decompensation and should be monitored closely during the first three to six months of therapy. Additional testing for prothrombin time in a cirrhotic patient with marked increases in aminotransferases is prudent. If the patient decompensates, they should be seen in a transplant center as soon as possible. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.) </p><p class="headingAnchor" id="H33402535"><span class="h2">Drug-induced liver injury</span><span class="headingEndMark"> — </span>Patients with HIV and chronic viral hepatitis (either HBV or hepatitis C virus [HCV]) may be at increased risk for drug-induced liver injury [<a href="#rid10">10,11</a>]. Certain older antiretroviral medications have a higher risk of drug-induced liver injury and should be used with caution in the patient with liver disease (eg, <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a>) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/3640.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in patients living with HIV", section on 'HBV and risk of drug-induced hepatotoxicity'</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p class="headingAnchor" id="H33402542"><span class="h2">Emergence of HBV drug resistance</span><span class="headingEndMark"> — </span>HIV/HBV-coinfected patients may develop HBV drug resistance with subsequent hepatitis flares associated with rebound viremia [<a href="#rid13">13</a>]. The diagnosis of HBV drug resistance is suspected if the patient has attained viral suppression with subsequent detection of viremia or in the patient who has an increase in viral load more than 1 log above the previous value. (See <a class="local">'HBV drug resistance testing'</a> below.)</p><p>The risk of resistance is high in patients who are being treated with an ART regimen that contains <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> or <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> as the only agent active against HBV. By contrast, resistance to tenofovir, even when it is the only HBV-active agent in a combination ART regimen, is very rare [<a href="#rid14">14</a>]. A detailed discussion of tenofovir resistance in patients with chronic HBV is presented in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/3656.html" rel="external">"Tenofovir and adefovir for the treatment of chronic HBV infection", section on 'Risk of resistance'</a>.)</p><p class="headingAnchor" id="H865640306"><span class="h2">Infection with other hepatitis viruses</span><span class="headingEndMark"> — </span>Infection with hepatitis D virus (HDV), HCV, or hepatitis A virus (HAV) can lead to a hepatitis flare. In the right epidemiologic setting, testing for these infections should be obtained. (See  <a class="medical medical_review" href="/z/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3666.html" rel="external">"Epidemiology, clinical manifestations and diagnosis of hepatitis D virus infection"</a>.)</p><p class="headingAnchor" id="H2013564859"><span class="h2">Steatotic liver disease</span><span class="headingEndMark"> — </span>Fluctuations in ALT level may be seen in association with weight gain or loss as well as alcohol use. (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">"Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"</a> and  <a class="medical medical_review" href="/z/d/html/3729.html" rel="external">"Evaluation of the patient with HIV and hepatobiliary complaints", section on 'Hepatic steatosis'</a>.)</p><p class="headingAnchor" id="H33402549"><span class="h1">HBV DRUG RESISTANCE TESTING</span><span class="headingEndMark"> — </span>Although preliminary data suggest that resistance testing may have a role in drug selection, there are few published studies in this area. </p><p>Hepatitis B virus (HBV) has a high replication rate, with an estimated 10<sup>12</sup> viruses being produced daily in the treatment-naive host [<a href="#rid15">15</a>]. During replication, HBV mutations arise at a frequency of 1 per 10<sup>4</sup> to 10<sup>5</sup> nucleotides [<a href="#rid16">16</a>]. The combination of these two factors leads to a swarm of viral variants called "quasispecies," similar to that described for HIV and hepatitis C viruses (HCV). However, despite the high HBV mutation rate, the emergence of drug resistance occurs more slowly for HBV than for HIV or HCV. This may be related to several factors, including slow turnover of covalently closed circular DNA in chronically infected hepatocytes, the constraints on HBV evolution imposed by its overlapping reading frames, and the effect of the host immune response [<a href="#rid17">17</a>].</p><p>Drug resistance is inferred when a ≥1 log(10) international units/mL increase in viral load from nadir is documented on two consecutive serum samples collected at least one month apart in patients who initially responded to and are compliant with therapy [<a href="#rid18">18</a>]. Identification of antiviral resistance involves the detection of mutations in the HBV genome (typically polymerase) that have been selected during treatment [<a href="#rid18">18</a>]. Many clinical laboratories now combine resistance testing with genotyping. (See  <a class="medical medical_review" href="/z/d/html/3644.html" rel="external">"Clinical significance of hepatitis B virus genotypes"</a>.)</p><p>Drug resistance is most common in patients who had or have a detectable HBV DNA while on antiretroviral therapy with <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> as the only HBV-active agent. Some experts recommend drug resistance testing, especially if the addition of <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">entecavir</a> is being considered, since entecavir has overlapping resistance patterns with lamivudine. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'When entecavir is used'</a>.)</p><p class="headingAnchor" id="H33402571"><span class="h1">MONITORING FOR DRUG SIDE EFFECTS</span><span class="headingEndMark"> — </span>HIV/HBV-coinfected patients typically receive a tenofovir-containing antiretroviral therapy (ART) regimen. We check routine laboratory studies (eg, serum creatinine, urinalysis) based upon guideline recommendations for monitoring patients with HIV receiving ART [<a href="#rid19">19</a>]; these are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p><p>Tenofovir is available in two preparations, <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) and <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF). On occasion, TDF can lead to renal impairment, and the TAF formulation is associated with less renal toxicity. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Tenofovir'</a>.) </p><p>A more detailed discussion of the side effects associated with the agents used to treat HBV and the approach to patients who develop renal insufficiency on tenofovir are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'Antiviral Medications for HBV'</a> and  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'Renal insufficiency on tenofovir'</a>.)</p><p class="headingAnchor" id="H33402578"><span class="h1">DURATION OF HBV THERAPY</span><span class="headingEndMark"> — </span>Most patients with HIV and hepatitis B virus (HBV) coinfection will receive indefinite treatment for HIV and HBV. This is based upon the chronic nature of HBV infection and that patients with HIV require lifelong antiretroviral therapy. A more detailed discussion of the duration of therapy is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H4272795473"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H33402621"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – Laboratory monitoring during HBV therapy includes serial aminotransferases and assessment of viral suppression. </p><p></p><p class="bulletIndent1">We typically monitor HBV DNA and aminotransferases every three months to confirm the viral load is decreasing appropriately (eg, &lt;500 copies/mL by six months); we then reduce the frequency to every six months. (See <a class="local">'Patient monitoring during HBV therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for hepatocellular carcinoma</strong> – Patients with chronic HBV infection should be screened at baseline for the presence of hepatocellular carcinoma. We then obtain an ultrasound (with or without alpha fetoprotein [AFP]) every six months in those with evidence of advanced fibrosis or cirrhosis and in those over age 40 years. (See <a class="local">'Screening for hepatocellular carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with elevated aminotransferase levels</strong> – Fluctuations in aminotransferases in patients with HIV/HBV coinfection may be due to chronic HBV infection, drug toxicity, immune reconstitution inflammatory syndrome, inadequate adherence, the emergence of HBV drug resistance, infection with another hepatitis virus, or steatotic liver disease. (See <a class="local">'Abnormalities of aminotransferases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of resistance testing</strong> – HBV drug resistance testing may be useful in select patients (eg, those who received <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> without tenofovir), especially if treatment with <a class="drug drug_general" data-topicid="8816" href="/z/d/drug information/8816.html" rel="external">entecavir</a> is being considered. (See <a class="local">'HBV drug resistance testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are taking <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) as part of their antiretroviral therapy regimen should have routine laboratory monitoring (eg, serum creatinine and a urinalysis) to evaluate for drug-related side effects. (See <a class="local">'Monitoring for drug side effects'</a> above and  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health 2017; 2:e35.</a></li><li><a class="nounderline abstract_t">Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49:S112.</a></li><li><a class="nounderline abstract_t">Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.</a></li><li><a class="nounderline abstract_t">Grant JL, Agaba P, Ugoagwu P, et al. Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV. J Antimicrob Chemother 2019; 74:2003.</a></li><li><a class="nounderline abstract_t">Vinikoor MJ, Sinkala E, Chilengi R, et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis 2017; 64:1343.</a></li><li><a class="nounderline abstract_t">Wandeler G, Mauron E, Atkinson A, et al. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. J Hepatol 2019; 71:274.</a></li><li><a class="nounderline abstract_t">Soriano V, Barreiro P, Martín-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007; 195:1181.</a></li><li><a class="nounderline abstract_t">Collins JM, Raphael KL, Terry C, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis 2015; 61:1304.</a></li><li><a class="nounderline abstract_t">Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017; 31:2035.</a></li><li><a class="nounderline abstract_t">Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277.</a></li><li><a class="nounderline abstract_t">Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.</a></li><li><a class="nounderline abstract_t">Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.</a></li><li><a class="nounderline abstract_t">Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032.</a></li><li><a class="nounderline abstract_t">Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019; 70:1093.</a></li><li><a class="nounderline abstract_t">Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398.</a></li><li><a class="nounderline abstract_t">Günther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52:25.</a></li><li><a class="nounderline abstract_t">Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275.</a></li><li><a class="nounderline abstract_t">Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12 Suppl 3:H15.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on August 02, 2023).</li></ol></div><div id="topicVersionRevision">Topic 16129 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29249478" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19399795" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Benefits and risks of nucleoside analog therapy for hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551579" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31225612" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changes in liver stiffness after ART initiation in HIV-infected Nigerian adults with and without chronic HBV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28158504" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30965070" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17357055" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26082511" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692539" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577540" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786975" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090386" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antiretroviral drugs and liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452630" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30794889" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633078" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Viral dynamics in hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Naturally occurring variants of hepatitis B virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301976" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284179" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
